Log In
Print
BCIQ
Print
Print this Print this
 

Exalgo, Jurnista (NMED-1077) (formerly Oros hydromorphone)

Also known as: hydromorphone extended release tablets (formerly AP-77)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionExtended-release formulation of hydromorphone hydrochloride
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsManage moderate to severe pain in opoid-tolerant patients; Treat chronic osteoarthritis (OA) pain; Treat severe pain
Regulatory Designation

Partner

Epirus Biopharmaceuticals Inc.; Mallinckrodt plc


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$28.8M

$28.8M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today